表紙
市場調查報告書

伴隨式診斷市場 - 未來的診斷技術:個人化的預測/分析 (資金來源/應用),新冠病毒傳染病 (Covid-19) 的影響,行政及顧問指南 (2020∼2024年)

Companion Diagnostic Markets - the Future of Diagnostics. by Funding Source and Application with Customized Forecasting/analysis, Covid Updates, and Executive and Consultant Guides 2020-2024

出版商 Howe Sound Research 商品編碼 939940
出版日期 內容資訊 英文 429 Pages
商品交期: 最快1-2個工作天內
價格
伴隨式診斷市場 - 未來的診斷技術:個人化的預測/分析 (資金來源/應用),新冠病毒傳染病 (Covid-19) 的影響,行政及顧問指南 (2020∼2024年) Companion Diagnostic Markets - the Future of Diagnostics. by Funding Source and Application with Customized Forecasting/analysis, Covid Updates, and Executive and Consultant Guides 2020-2024
出版日期: 2020年06月03日內容資訊: 英文 429 Pages
簡介

伴隨式診斷在診斷業界引起革命。市場終於走出研究室轉移至臨床現場。由腫瘤,特別是癌症免疫腫瘤學主導市場。FDA打開這扇通向未來診斷技術的大門。另一方面,由於新冠病毒 (Covid-19) 擴大傳染對醫療市場帶來巨大影響,特殊癌症檢查的需求因此減少。

此報告針對伴隨式診斷未來的技術進步/市場成長前景進行分析,統整以下資訊,包括:技術性概述及主要應用領域/主要活用領域,對未來醫療現場的影響力,目前的主要開發/產品上市的趨勢,主要企業簡介以及主力產品,未來市場規模的趨勢前景,按地區/應用/資金來源劃分的詳細趨勢,新冠病毒(Covid-19)發生後的影響。

目次

i. 伴隨式診斷市場:策略狀況分析

ii. 給行政/行銷/銷售/業務開發人員的建議

iii. 經營諮詢/投資顧問建議

第1章 簡介,市場定義

第2章 市場概述

  • 動力市場中的參與企業
    • 教育/研究機構
    • 診斷檢查的開發業者
    • 測量儀器供應商
    • 試劑的經銷商/供應商
    • 獨立測試實驗室
    • 國營/公營實驗室
    • 醫院實驗室
    • 執業醫生
    • 監察機構
    • 認證機構
  • 個人化醫療及伴隨式診斷
    • 基本
    • 方法
    • 疾病風險評估
    • 用途
    • 診斷及干預
    • 藥物開發及使用
    • 呼吸蛋白體
    • 癌症基因體
    • 人口篩檢
    • 挑戰
    • 監管
    • 智慧財產權
    • 患者隱私權及機密性
  • 染色體,基因,表觀遺傳學
  • 癌症基因
    • 生殖細胞及體細胞
    • 臨床角色的變化
  • 產業結構達成目標
    • 新藥物的資金市場
    • 規模經濟
    • 執業醫師
    • 醫師及與即時檢測(POCT)

第3章 市場趨勢

  • 市場成長的成長因素
  • 市場成長的阻礙因素
  • 儀器及自動化
  • 診斷技術的開發
    • 次世代定序:推動革命
    • 單細胞基因體:改變局面
    • 藥物基因體:診斷及治療一條龍
    • CGES測試:開拓新世界
    • 生物晶片/巨磁阻效應的化驗

第4章 伴隨式診斷:近年來的進展

  • 這個領域的重要性及活用方法

第5章 主要企業簡介

  • 10x Genomics, Inc.
  • Abbott Diagnostics
  • AccuraGen Inc
  • Adaptive Biotechnologies
  • Aethlon Medical
  • Agena Bioscience, Inc
  • Agilent
  • Anchor Dx
  • ANGLE plc
  • ApoCell, Inc.
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • AVIVA Biosciences
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc
  • Biodesix Inc.
  • BioFluidica
  • BioIVT
  • Biolidics Ltd
  • bioMérieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bio-Reference Laboratories
  • Bio-Techne
  • Bioview
  • Bolidics
  • Boreal Genomics
  • Bristol-Myers Squibb
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • Castle Biosciences, Inc.
  • CellMax Life
  • Cepheid (now Danaher)
  • Charles River Laboratories
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp.
  • CytoTrack
  • Datar Cancer Genetics Limited
  • Diagnologix LLC
  • Diasorin S.p.A.
  • Enzo Life Sciences, Inc.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Exosome Diagnostics
  • Exosome Sciences
  • Fabric Genomics
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine (now Roche)
  • Freenome
  • FUJIFILM Wako Diagnostics
  • GeneFirst Ltd.
  • Genetron Health (Beijing) Co., Ltd
  • Genomic Health
  • GenomOncology
  • GILUPI Nanomedizin
  • Grail, Inc.
  • Guardant Health
  • HalioDx
  • HansaBiomed
  • HeiScreen
  • Helomics
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invivogen
  • Invivoscribe
  • Janssen Diagnostics
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Menarini Silicon Biosystems
  • Miltenyi Biotec
  • MIODx
  • miR Scientific
  • Molecular MD
  • MyCartis
  • Myriad Genetics/Myriad RBM
  • NantHealth, Inc.
  • Natera
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd.
  • Oncocyte
  • OncoDNA
  • Ortho Clinical Diagnostics
  • Oxford Nanopore Technologies
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Qiagen Gmbh
  • Rarecells SAS
  • RareCyte
  • Roche Molecular Diagnostics
  • Screencell
  • Sense Biodetection.
  • Serametrix
  • Siemens Healthineers
  • Silicon Biosystems
  • simfo GmbH
  • Singlera Genomics Inc.
  • Singulomics
  • SkylineDx
  • Stratos Genomics
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Thrive Earlier Detection
  • Todos Medical
  • Trovagene
  • Volition
  • Vortex Biosciences

第6章 全球伴隨式診斷市場

  • 各國分析概述
  • 各應用概述
  • 各資金來源趨勢/預測:趨勢

第7章 全球伴隨式診斷市場:不同應用

  • 腫瘤
  • 神經內科
  • 心臟病學
  • 其他

第8章 全球伴隨式診斷市場:資金來源

  • 製藥企業
  • 製造商
  • 臨床醫療機構
  • 其他

附錄

目錄

OVERVIEW:

Companion Diagnostics are poised to revolutionize the diagnostics industry. The market is finally moving out of the lab and into the clinic. Oncology, especially immune-oncology is leading the way. And the FDA is holding the door open for this diagnostic technology of the future. But COVID-19 is impacting healthcare treatment everywhere and lowering demand for specialized cancer testing. Find out the latest outlook for this important market.

Will Personalized Companion Diagnostics become the norm for diagnostics?

Learn all about how diagnostic players are jockeying for position with their pharmaceutical counterparts and creating new and significant business opportunities. And some players are already taking the lead. It is a dynamic market situation with enormous opportunity. Diagnostic companies are trying to back the right horse. The science is racing forward. And the cost of molecular diagnostics continues to fall.

The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country or specific area in the world is available to purchasers of the report.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

i. Companion Diagnostic Market - Strategic Situation Analysis

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1 What are Companion Diagnostics?
  • 1.2 The Personalized Medicine Revolution
  • 1.3 Market Definition
    • 1.3.1 Revenue Market Size
  • 1.4 Methodology
    • 1.4.1 Authors
    • 1.4.2 Sources
  • 1.5 A Spending Perspective on Clinical Laboratory Testing
    • 1.5.1 U.S. Medicare Expenditures for Laboratory Testing

2. Market Overview

  • 2.1 Players in a Dynamic Market
    • 2.1.1 Academic Research Lab
    • 2.1.2 Diagnostic Test Developer
    • 2.1.3 Instrumentation Supplier
    • 2.1.4 Distributor and Reagent Supplier
    • 2.1.5 Independent Testing Lab
    • 2.1.6 Public National/regional lab
    • 2.1.7 Hospital lab
    • 2.1.8 Physician Office Labs
    • 2.1.9 Audit Body
    • 2.1.10 Certification Body
  • 2.2 Personalized Medicine and Companion Diagnostics
    • 2.2.1 Basics
    • 2.2.2 Method
    • 2.2.3 Disease risk assessment
    • 2.2.4 Applications
    • 2.2.5 Diagnosis and intervention
      • 2.2.5.1 Companion Diagnostics
    • 2.2.6 Drug development and usage
    • 2.2.7 Respiratory proteomics
    • 2.2.8 Cancer genomics
    • 2.2.9 Population screening
    • 2.2.10 Challenges
    • 2.2.11 Regulatory oversight
    • 2.2.12 Intellectual property rights
    • 2.2.13 Reimbursement policies
    • 2.2.14 Patient privacy and confidentiality
  • 2.3 Chromosomes, Genes and Epigenetics
    • 2.3.1 Chromosomes
    • 2.3.2 Genes
    • 2.3.3 Epigenetics
  • 2.4 Cancer Genes
    • 2.4.1 Germline vs Somatic
    • 2.4.2 Changing Clinical Role
  • 2.5 Structure of Industry Plays a Part
    • 2.5.1 New Pharmaceutical Funding Market
    • 2.5.2 Economies of Scale
      • 2.5.2.1 Hospital vs. Central Lab
    • 2.5.3 Physician Office Labs
    • 2.5.4 Physicians and POCT

3. Market Trends

  • 3.1 Factors Driving Growth
    • 3.1.1 Level of Care
    • 3.1.2 Immuno-oncology
    • 3.1.3 Liability
    • 3.1.4 Aging Population
  • 3.2 Factors Limiting Growth
    • 3.2.1 State of knowledge
    • 3.2.2 Genetic Blizzard.
    • 3.2.3 Protocol Resistance
    • 3.2.4 Regulation and coverage
  • 3.3 Instrumentation and Automation
    • 3.3.1 Instruments Key to Market Share
    • 3.3.2 Bioinformatics Plays a Role
  • 3.4 Diagnostic Technology Development
    • 3.4.1 Next Generation Sequencing Fuels a Revolution.
    • 3.4.2 Single Cell Genomics Changes the Picture
    • 3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment
    • 3.4.4 CGES Testing, A Brave New World
    • 3.4.5 Biochips/Giant magneto resistance based assay

4. Companion Diagnostics Recent Developments

  • 4.1 Recent Developments - Importance and How to Use This Section
    • 4.1.1 Importance of These Developments
    • 4.1.2 How to Use This Section
      • FDA Approval for FoundationOne®CDx
      • FDA finalizes CDx Guidance
      • QIAGEN Launches CDx Therascreen BRAF Test
      • Myriad Genetics Seeks Approval for Companion Diagnostic
      • ARUP Labs Seek PMA for Hemophilia Gene Therapy CDx
      • QIAGEN Builds on Global Collaboration with Amgen
      • Foundation Medicine nabs 19th companion Dx
      • Maze Therapeutics Uses CRISPR for Precision Medicine Companion Diagnostics
      • Myriad Wins Japanese Approval for BRACAnalysis
      • Fujitsu Improves Efficiency in Cancer Genomic Medicine
      • Thermo Fisher's automated sequencer to offer same-day, pan-cancer test results
      • Takeda, Prometheus Enter IBD Drug-Companion Diagnostic Partnership
      • Thermo Fisher, Eli Lilly Ink CDx Collaboration in NSCLC, Thyroid Cancer
      • Roche VENTANA PD-L1 (SP142) Assay approved as companion diagnostic
      • Universal Genetic Testing for All Breast Cancer Patients
      • Exact Sciences buys Genomic Health
      • Biodesix Highlights Pipeline and Companion Diagnostic Development
      • Multi-Gene Liquid Biopsy Breast Cancer Panel
      • New Gene Panel Identifies High Risk Prostate Cancer
      • Guardant Health Liquid Biopsy Test to be Covered by EviCore
      • Inivata Completes £39.8M Series B Funding Round
      • Bio-Rad Clinical ddPCR Test, Diagnostic System Get FDA Clearance
      • CellMax, Medigen Biotech Partner in Colorectal Cancer Clinical Trials

5. Profiles of Key Players

  • 10x Genomics, Inc.
  • Abbott Diagnostics
  • AccuraGen Inc
  • Adaptive Biotechnologies
  • Aethlon Medical
  • Agena Bioscience, Inc
  • Agilent
  • Anchor Dx
  • ANGLE plc
  • ApoCell, Inc.
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • AVIVA Biosciences
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc
  • Biodesix Inc.
  • BioFluidica
  • BioIVT
  • Biolidics Ltd
  • bioMérieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bio-Reference Laboratories
  • Bio-Techne
  • Bioview
  • Bolidics
  • Boreal Genomics
  • Bristol-Myers Squibb
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • Castle Biosciences, Inc.
  • CellMax Life
  • Cepheid (now Danaher)
  • Charles River Laboratories
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp.
  • CytoTrack
  • Datar Cancer Genetics Limited
  • Diagnologix LLC
  • Diasorin S.p.A.
  • Enzo Life Sciences, Inc.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Exosome Diagnostics
  • Exosome Sciences
  • Fabric Genomics
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine (now Roche)
  • Freenome
  • FUJIFILM Wako Diagnostics
  • GeneFirst Ltd.
  • Genetron Health (Beijing) Co., Ltd
  • Genomic Health
  • GenomOncology
  • GILUPI Nanomedizin
  • Grail, Inc.
  • Guardant Health
  • HalioDx
  • HansaBiomed
  • HeiScreen
  • Helomics
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invivogen
  • Invivoscribe
  • Janssen Diagnostics
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Menarini Silicon Biosystems
  • Miltenyi Biotec
  • MIODx
  • miR Scientific
  • Molecular MD
  • MyCartis
  • Myriad Genetics/Myriad RBM
  • NantHealth, Inc.
  • Natera
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd.
  • Oncocyte
  • OncoDNA
  • Ortho Clinical Diagnostics
  • Oxford Nanopore Technologies
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Qiagen Gmbh
  • Rarecells SAS
  • RareCyte
  • Roche Molecular Diagnostics
  • Screencell
  • Sense Biodetection.
  • Serametrix
  • Siemens Healthineers
  • Silicon Biosystems
  • simfo GmbH
  • Singlera Genomics Inc.
  • Singulomics
  • SkylineDx
  • Stratos Genomics
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Thrive Earlier Detection
  • Todos Medical
  • Trovagene
  • Volition
  • Vortex Biosciences

6. The Global Market for Companion Diagnostics

  • 6.1 Global Market Overview by Country
    • 6.1.1 Table - Global Market by Country
    • 6.1.2 Chart - Global Market by Country
  • 6.2 Global Market by Application - Overview
    • 6.2.1 Table - Global Market by Application
    • 6.2.2 Chart - Global Market by Application - 2019/2024 Comparison
    • 6.2.3 Chart - Global Market by Application - 2019
    • 6.2.4 Chart - Global Market by Application -2024
    • 6.2.5 Chart - Global Market by Application - Share by Year
  • 6.3 Global Market Funding Source - Overview
    • 6.3.1 Table - Global Market by Funding Source
    • 6.3.2 Chart - Global Market Funding Source - 2019/2024 Comparison
    • 6.3.3 Chart - Global Market Funding Source - 2019
    • 6.3.4 Chart - Global Market Funding Source -2024
    • 6.3.5 Chart - Global Market Funding Source - Share by Year

7. Global Companion Diagnostic Markets - By Application

  • 7.1 Oncology
    • 7.1.1 Table Oncology - by Country
    • 7.1.2 Chart - Oncology Growth
  • 7.2 Neurology
    • 7.2.1 Table Neurology - by Country
    • 7.2.2 Chart - Neurology Growth
  • 7.3 Cardiology
    • 7.3.1 Table Cardiology - by Country
    • 7.3.2 Chart - Cardiology Growth
  • 7.4 Other Application
    • 7.4.1 Table Other Application - by Country
    • 7.4.2 Chart - Other Application Growth

8. Global Companion Diagnostic Markets - Funding Source

  • 8.1 Global Market Pharmaceutical
    • 8.1.1 Table Pharmaceutical - by Country
    • 8.1.2 Chart - Pharmaceutical Growth
  • 8.2 Global Market Venture
    • 8.2.1 Table Venture - by Country
    • 8.2.2 Chart - Venture Growth
  • 8.3 Global Market Clinical
    • 8.3.1 Table Clinical - by Country
    • 8.3.2 Chart - Clinical Growth
  • 8.4 Global Market Other Funding
    • 8.4.1 Table Other Funding - by Country
    • 8.4.2 Chart - Other Funding Growth

Appendices

  • I. United States Medicare System: January 2020 Clinical Laboratory Fees Schedule
  • II. Pharmacogenomic Biomarkers in Drug Labeling

Table of Tables

  • Table 1 Lab Spending 2014 to 2024
  • Table 2 Medicare Clinical Lab Expenditures Actual & Forecast 2004 to 2020 ($Billion)
  • Table 3 Market Players by Type
  • Table 4 The Base Pairs
  • Table 5 Five Factors Driving Growth
  • Table 6 Four Factors Limiting Growth
  • Table 7 Key Diagnostic Laboratory Technology Trends
  • Table 8 Next Generation Sequencing Technologies - Speed and Cost
  • Table 9 - Global Companion Diagnostic Market by Region
  • Table 10 Global Market by Application
  • Table 11 Global Market by Funding Source
  • Table 12 Oncology by Country
  • Table 13 Neurology by Country
  • Table 14 Cardiology by Country
  • Table 15 Other Application by Country
  • Table 16 Pharmaceutical by Country
  • Table 17 Venture by Country
  • Table 18 Clinical by Country
  • Table 19 Other Funding by Country
  • Table 22 Pharmacogenomic Biomarkers

Table of Figures

  • Figure 1 FDA Approved Companion Diagnostics
  • Figure 2 Clinical Lab Spending 2014 to 2024
  • Figure 3 Medicare Clinical Lab Expenditures 2004 to 2020 ($Million)
  • Figure 4 DNA Strands and Chromosomes
  • Figure 5 Karyogram of Human Chromosomes
  • Figure 6 Size of Various Genomes
  • Figure 7 Germline vs Somatic Mutations
  • Figure 8 Comparing Genomic Diagnostic and Traditional Testing
  • Figure 9 Percentage of World Population Over 65
  • Figure 10 2019 Global Market Density Chart
  • Figure 11 CDx Market by Application - 2019 vs. 2024
  • Figure 12 CDx Market by Application 2019
  • Figure 13 CDx Market by Application 2024
  • Figure 14 Application Type Share by Year
  • Figure 15 Funding Source - 2019 vs. 2024
  • Figure 16 Funding Source Market 2019
  • Figure 17 Funding Source Market 2024
  • Figure 18 Funding Source Share by Year
  • Figure 19 Oncology Growth
  • Figure 20 Neurology Growth
  • Figure 21 Cardiology Growth
  • Figure 22 Other Application Growth
  • Figure 23 Pharmaceutical Growth
  • Figure 24 Venture Growth
  • Figure 25 Clinical Growth
  • Figure 26 Other Funding Growth
  • Figure 27 2020 Clinical Laboratory Fee Schedule